Company
ASX:RGT
Argent BioPharma Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. Argent BioPharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
157 stories · page 6 of 8
MGC will continue to be responsible for seeking regulatory authorisation in these territories, while Sciensus Rare will be responsible for applications to early-access and named-patient programmes
Sales amounted to US$1.8mln in the fourth quarter, with COVID-19 treatment ArtemiC accounting for 60% of the total
Woolworths had proposed to acquire API at a cash offer price of $1.75 a share, however, said it could not validate the financial returns it requires in line with the group’s capital allocation framework.
Managing director Roby Zomer says MGC is “pleased to have the opportunity to alleviate the symptoms of COVID-19 in one of the largest populated countries in the world”
Swiss PharmaCan and Glow LifeTech are carrying out the research which should be complete in February
It said it plans to begin the approval process for CimetrA in India before rolling it out to a total of five countries in central and eastern Europe and central Asia
“With the continuing outbreaks of COVID-19, not only in Europe but globally, we expect to see continued growth in the demand for COVID-19 treatments for those people who contract the disease,” says MD.
The bio-pharma group also announced that AMC has engaged Morgan Lewis & Bockius, a leading US pharmaceutical sector law firm, to seek FDA approval for its CimetrA product
The company is now moving onto the equipment fit-out and commissioning phase
The Israeli authorities will oversee the study, which will involve 240 people in three countries
The latest quarter delivered nearly US$1mln of cash receipts and US$564,000 of Phytocannabinoid medicine sales
Early prevention of cytokine storm appears to be an effective method of treatment in mild and moderate COVID-19 cases.
The US$3mln purchase order is for CimetrA, MGC’s curcumin and Boswellia compound, which has shown early promise in treating the symptoms of COVID-19
The order of 1,000 units of CimetrA is part of a landmark deal with AMC worth a minimum of US$24mln
Wednesday's statement brought two significant developments for the ArtemiC product group
CannEpil+ will be made available for free on compassionate grounds to ten patients with refractory epilepsy for six months, as part of a trial
The group's co-founder and managing director, Roby Zomer, said: "We are pleased to have secured a license to import CimetrA as an Emergency Use Drug in India, and hope that we can secure approval swiftly to expand its availability to a much
Revenues in the year to end June 2021 rose 43% with phytocannabanoid sales up 69%
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
MGC Pharmaceuticals Ltd has been a huge winner today, up 43.59%. MXC has signed a landmark deal with an American drug distributor worth a minimum US$24 million over the next three years.
